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Several assumptions about elevations of macromolecular markers of myocardial injury in
blood require critical consideration. The dichotomy of modest, persistent elevations of
troponins I and T as prognostic factors in patients with unstable angina and absent elevations
of isoenzymes of creatine kinase is presently unexplained. Factors influencing the appearance
of macromolecular markers of myocardial injury in blood are considered, including the need
to estimate baseline values, to consider elevations as deviations from baseline rather than
simply points within a distribution of baseline values in normal subjects, to recognize
operative biochemical and physiologic determinants of marker release from injured myocytes
and washout and to take into account the influence of apoptosis. Elucidation and consider-
ation of mechanisms underlying the appearance of specific macromolecular markers in blood
appear likely to improve diagnosis and explain the prognostic power of the troponins in
patients with unstable angina. Detection of proteolytic breakdown products of troponins in
blood is likely to explain the modest, persistent elevations seen in some patients with unstable
angina and their prognostic implications. (J Am Coll Cardiol 2000;35:1355–8) © 2000 by
the American College of Cardiology
Karmen (then a medical student), Wroblewski and LaDue
(1) revolutionized cardiology when they showed that ele-
vated activities in blood of enzymes from necrotic myocar-
dium establish the diagnosis of acute myocardial infarction
(AMI). Almost 50 years later, diverse macromolecular
markers are commonplace cornerstones of diagnosis. How-
ever, subtle quantitative considerations remain inadequately
appreciated, and conundrums persist. One is the prognostic
power of increased concentrations in blood of the thin-
filament cardiac regulatory proteins troponins I and T (TnI
and TnT) in patients with unstable angina in predicting
subsequent coronary events (2,3). Conventional wisdom
does not adequately explain their proven predictive power,
and interpretations are clouded by a reflex to resort to
comparing macromolecular markers in terms of which is
“best.”
In addition to diagnostic difficulties resulting from occa-
sional laboratory errors and inadequate timing or flawed
acquisition of blood samples, contributions to blood levels of
macromolecular markers from unrecognized noncardiac
sources can compromise interpretation. Several fallacies may
also obscure accurate diagnosis.
DISCUSSION
Fallacies reflecting ignorance of baseline values. The
results of assays of transaminases, lactate dehydrogenase
(LDH), creatine kinase (CK), isoenzymes of these enzymes,
and TnI and TnT are generally reported as normal or
abnormal with respect to a range indicative of the distribu-
tion of values in a normal population. However, a five-fold
increase in activity in blood of the myocardial band (MB)
isoenzyme of CK (from 1 to 5 IU/L in a hypothetical
instance) is more indicative of AMI than is recognition of
an “abnormal” value of 9 IU/L in a subject whose baseline
value is 9, even though 9 IU/L may be present under
physiologic conditions in only a small number of subjects.
What is being inferred is the amount of enzyme released
from the heart that results in a given increase in activity in
blood (4). The inference cannot be made without knowl-
edge of or assumption of a baseline value in a given
individual subject. Hence the need for diagnosis based on
serial determinations and estimation of a time-activity
curve. Myocardial infarction (MI) cannot be excluded by a
single “normal” value nor established by a single “abnormal,
elevated” value.
Fallacies reflecting unrecognized determinants of release
ratios and clearance of specific macromolecular markers.
Factors determining the rate of appearance in blood of a
macromolecular marker released from myocardium include
molecular weight, charge, binding to intra- and extracellular
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components, degradation intracellularly and in the lymph
and interstitial fluid as well as in the blood itself, and
clearance via the kidney, liver or reticuloendothelial system
(5). Even if the intramyocardial concentrations of two
macromolecular markers are identical, time to occurrence in
blood of a detectable increase over baseline, specific values
attained, time to occurrence of peak values, persistence of
elevations above “normal,” and the entire shape of the area
under the time–activity or time–concentration curve of each
can differ markedly. Accurate diagnostic and prognostic
interpretations require knowledge of determinants of the
behavior of the macromolecular marker being utilized.
Fallacies reflecting flawed assumptions about the nature
of cardiac cell death. Myocardium subjected to lethal
ischemia undergoes either necrosis or apoptosis. Both occur
in any given infarct (6). Macromolecules are readily released
from myocytes undergoing necrosis but not from those
undergoing apoptosis. As noted recently in a comprehensive
review (6) “apoptosis coexists with necrosis in every AMI.”
Thus, time–activity and time–concentration curves in blood
will depend on the proportion of myocytes within a given
infarct undergoing each type of cell death. As James has
pointed out “it must be reasonably assumed that these dead
(apoptotic) myocytes do not release . . . intracellular en-
zymes” (6). This may explain the rare and confusing false
negative results in patients with ultimately proven infarction
as judged from electrocardiographic, echocardiographic, and
angiographic data. Another potential cause of such false
negative occurrences is complete lack of washout (as dis-
cussed later) due to complete occlusion of an infarct-related
artery and absence of collateral flow.
Fallacies reflecting assumptions regarding the source of
macromolecular markers appearing in blood. After the
onset of MI the amount of CK appearing in blood is directly
related to the number of myocytes that become necrotic
(7,8). The amount recoverable from blood has been thought
by many to be less than the total initially residing in necrotic
cells because of degradation in lymph and other compart-
ments. In an elegant study, Hermens et al. (9) have found
that complete recovery of hydroxybutyric acid dehydroge-
nase (HBD) and CK lost from myocytes can be calculated.
However, the result depends on assumed disappearance
constants (derived from multicompartmental modeling) for
both HBD and CK. The fact that complete recovery is
calculable for both enzymes raises another problem, namely,
accounting for the likely impact of red cells on accumulation
of HBD but not CK in blood in a hemorrhagic infarct. In
fact, the amount of HBD (also called LDH-1 and heat-
stable LDH) in red blood cells in a hemorrhagic infarct
often substantially exceeds the amount present in myocar-
dial cells undergoing necrosis. Because red blood cells are
rich in HBD, that is, the “myocardial” LDH isoenzyme, a
hemorrhagic infarct will elaborate much more HBD, and a
disproportionate amount of HBD compared with CK, than
will a bland infarct. Comparable peak activities of HBD in
blood do not imply comparable infarct size in the two
circumstances.
Fallacies reflecting inadequate consideration of lack of
washout. Given the same amount of myocardial macromo-
lecular marker released into the extracellular fluid, the peak
concentration in blood will depend on the rapidity of
washout from the heart. Thus, in a patient in whom the
infarct-related artery is spontaneously, pharmacologically, or
mechanically recanalized, the time of occurrence of peak
will be abbreviated, and the peak concentration in blood will
be augmented, often markedly, compared with what would
have occurred in the absence of restoration of patency. Valid
prognostic inferences based on absolute values must be
predicated on knowledge of the setting and determinations
of macromolecular marker release in a given patient and on
analysis of time-activity curves, rather than on peak values
alone (10).
Potentially spurious assumptions regarding the nature of
the troponin/CK dichotomy and factors underlying re-
lease of each. In the case of typical Q-wave infarction,
characteristic time-activity of CK and time–concentration
curves of TnI and TnT are evident. Though the two types
of curves differ markedly from each other, the relationship
between them is consistent (11). The diagnostic sensitivity
and specificity provided by each are virtually the same.
These phenomena are consistent with a commonality of
determinants of release of both types of macromolecular
markers into blood from myocytes undergoing cell death.
However, in patients with unstable angina without infarc-
tion, CK values do not increase but TnI, TnT or both may
exceed “the upper limit of normal.” Furthermore, minimal
elevations generally persist for hours or days. The conven-
tional wisdom, often not rendered explicitly, is that smol-
dering, low-level necrosis is ongoing in such patients and
that increases in TnI and TnT therefore reflect “increased
diagnostic sensitivity” of the troponins compared with that
of CK. Moreover, it is believed that the smoldering necrosis
is a determinant of an increased likelihood of a subsequent
acute coronary event. Although the prognostic implications
of such elevations of TnI and TnT are unequivocal and
remarkable, it is not clear why. At least several possibilities
merit serious consideration.
Abbreviations and Acronyms
AMI 5 acute myocardial infarction
CK 5 creatine kinase
HBD 5 hydroxybutyric acid dehydrogenase
LDH 5 lactate dehydrogenase
MB 5 myocardial band
MI 5 myocardial infarction
TnC 5 troponin C
TnI 5 troponin I
TnT 5 troponin T
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In the context of the principles outlined earlier, it does
not appear likely that the mini-elevations of troponin truly
reflect smoldering necrosis secondary to ischemia. Insulted
myocytes recover, succumb, or hibernate. None of these
states is known to be associated with persistent “leaky”
sarcolemma or persistent elaboration of macromolecules
with release into blood. It is also difficult to envision any
such leaking as giving rise to sufficient release of troponin to
sustain modest elevations in the face of ongoing, albeit slow,
clearance. Can we envision other testable hypotheses delin-
eating mechanisms that could account for modest, sustained
elevations of TnI and TnT and their prognostic import?
The assumption that “cardiac” troponins are released
exclusively from cardiac myocytes could possibly be violated.
In patients with unstable angina the nature of the coronary
vascular disease per se may differ when the likelihood of a
subsequent coronary event is high. For example, more
extensive inflammation may be present, and this could
account for expression of troponin in cells other than cardiac
myocytes, such as vascular smooth muscle cells or cellular
constituents in vessels in the heart. Slow and persistent
release of the anomalously synthesized troponin could
explain the persistent elevation of its concentration in blood.
Assessment of putative sites of TnI and TnT elaboration by
immunohistochemical and in situ hybridization techniques
could illuminate this possibility.
Alternatively, clearance of troponins synthesized in myo-
cardium and released slowly (there is some normal turnover)
might be diminished in those patients with unstable angina
in whom the likelihood of a subsequent coronary event is
high. If so, “baseline” concentrations in blood would rise,
accounting for the persistent “elevations” indicative of a
poor prognosis. The assessment of renal and hepatic func-
tion as well as other factors potentially affecting clearance of
TnI and TnT and the use of immunoassay to detect
unrecognized degradation products could shed light on this
hypothesis.
What is perhaps the most likely explanation for the
modest, persistent elevations of the blood concentrations of
TnI and TnT is relatively straightforward. The immunoas-
says used to characterize concentrations in blood of these
macromolecular markers detect not only TnI and TnT, but
also proteolytic degradation products of each, as well as
covalently bound complexes of TnI-troponin C (TnC) and
TnT-TnC (12). Indeed, in association with myocardial
ischemia and infarction very little of what is identified in
blood as TnI with the use of conventional immunoassay
comprises free, unaltered protein (13,14).
In contrast, it appears that large amounts of unaltered
TnT are depleted from the heart (15). McDonough et al.
(14) recently characterized the time course of appearance in
myocardium and release into the coronary effluent of TnI
and its proteolytic breakdown products and covalently
bound complexes in association with mild and severe
ischemia followed by reperfusion in laboratory animals.
Troponin T and its breakdown products were studied as
well, but in less detail. Very small amounts of breakdown
products of TnI are present in blood under physiologic
conditions. Proteolysis products increase markedly with
ischemia followed by reperfusion. With progressively more
severe ischemia, the proportion of shorter chain length TnI
products increases. The calcium-activated protease, calpain,
may play a pivotal role in the degradation of the thin
filament (14,16,17), thereby potentially mediating impair-
ment of contractile function in stunned myocardium as well
(17). It is known that the extent of proteolysis of intracel-
lular myocardial contractile and cytoskeletal proteins in-
creases when the structural integrity of the myofilaments is
altered, and that proteolytic breakdown products may egress
more rapidly from cells compared with their parent struc-
tural proteins; this is why myosin light chains appear in
blood after MI. The fact that both TnI and TnT can be
detected in blood in normal subjects in very small amounts
is consistent with low level, physiologic egress of either
these macromolecules or their proteolytic breakdown prod-
ucts and covalently bound complexes, or both. If high risk
patients with unstable angina are also subject to repeated,
subclinical bouts of ischemia and myocardial stunning with
activation of calpain, loss of myofilament integrity and
egress of proteolytic breakdown products may ensue. It is
worthy of note that in the McDonough et al. (14) study the
duration of mild ischemia sufficient to cause release of TnI
degradation products was only 15 min, recognized to be an
interval too brief to induce cell death.
Alternatively, if increased proteolysis of myofilament
proteins reflects heightened intensity of inflammatory pro-
cesses in the heart, coronary vessels, or the organism as a
whole such as those seen in patients with type 2 diabetes,
elaboration and leakage of breakdown products into blood
might well be increased in a sustained fashion. In either
case, detection of proteolytic breakdown products by con-
ventional immunoassay may directly reflect the stability, or
lack thereof, of the underlying coronary artery disease and,
accordingly, the propensity for future acute coronary events.
This possibility can be tested readily by simply character-
izing TnI, possibly TnT, and the relative concentrations of
specific degradation products in blood samples from pa-
tients with acute myocardial infarction, unstable angina
with a good prognosis, and unstable angina with an adverse
subsequent outcome. The distribution of breakdown prod-
ucts should reflect the extent of proteolysis and the ratio of
myocardium undergoing frank necrosis to myocardium
subjected to repeated stunning or heightened inflammation,
or both.
Regardless of the explanation ultimately established, it is
appropriate to stop assuming that the powerful prognostic
impact of modest and sustained increases in concentrations
of troponins in blood implies that TnI, TnT, or both are
more sensitive markers compared with other macromolec-
ular markers of myocardial necrosis. In fact, persistent,
modest elevations of apparent concentration of TnI and
TnT in blood may reflect important underlying pathogenic
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processes contributing to an adverse prognosis in patients
with unstable angina that constitute attractive targets for
therapeutic intervention.
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